Education
About Us
Working with TipRanks
Follow Us
Arch Therapeutics (ARTHQ)
OTHER OTC:ARTHQ
ARTHQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.16 - $0.95
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.51K
Market Cap
$4.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta270.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,444,364
10 Day Avg. Volume4,641
30 Day Avg. Volume2,510
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Arch Therapeutics News
ARTHQ FAQ
What was Arch Therapeutics’s price range in the past 12 months?
Arch Therapeutics lowest stock price was $0.16 and its highest was $0.95 in the past 12 months.
What is Arch Therapeutics’s market cap?
Arch Therapeutics’s market cap is $4.00.
When is Arch Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Arch Therapeutics’s earnings last quarter?
Currently, no data Available
Is Arch Therapeutics overvalued?
According to Wall Street analysts Arch Therapeutics’s price is currently Overvalued.
Does Arch Therapeutics pay dividends?
Arch Therapeutics does not currently pay dividends.
What is Arch Therapeutics’s EPS estimate?
Arch Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Therapeutics have?
Arch Therapeutics has 4,444,364 shares outstanding.
What happened to Arch Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arch Therapeutics?
Currently, no hedge funds are holding shares in ARTHQ
Company Description
Arch Therapeutics
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
Arch Therapeutics (ARTHQ) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Scorpius Holdings
―
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―